|
Sep 25
|
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
|
|
Apr 4
|
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
|
|
Mar 15
|
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
|